Shots:
- The EC has approved Rinvoq (upadacitinib; 15mg, QD) for the treatment of pts (≥12yrs.) with non-segmental vitiligo (NSV) who are candidates for systemic therapy
- Approval was backed by the Viti-Up clinical program (M19-044; n=614), incl. 2 replicate trials assessing Rinvoq, where in Period A, pts were randomized to either Rinvoq or PBO for 48wks. & in Period 2, they entered 112wk. OLE, in which all pts received Rinvoq
- Rinvoq met both co-1EPs, showing improvements in total body (T-VASI 50) & facial repigmentation (F-VASI 75) at Wk. 48, plus achieved 2EPs, incl. stabilization of disease extent (T-VASI) in pts with actively progressing disease at baseline
Ref: PRnewswire | Image: AbbVie | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
